Real-world use of seladelpar in adults with primary biliary cirrhosis
Collects everyday treatment data from adults with primary biliary cirrhosis taking seladelpar.
Plain-language title generated from the registry record
Registry title: Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
Key facts
- Where
- Berlin, Frankfurt, Hamburg, Hanover, Heidelberg, Herne, Homburg, Jena, Kiel, Leipzig, Leverkusen, Lübeck, München, Münster, Nuremberg, Tübingen, and Wiesbaden, GermanySee the 20 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with primary biliary cirrhosis (PBC) who are treated with seladelpar in everyday care in Germany and Switzerland.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- PBC diagnosed according to EASL criteria.
- Earlier treatment
- People must be treated with seladelpar. People who took part in a phase I to IV trial of seladelpar for PBC cannot join.
Main reasons for not taking part
- Current or earlier participation in a phase I to IV clinical trial of seladelpar for PBC
- Pregnancy
- Breastfeeding
Read by machine on 13 November 2026.
Where in Germany
- Charité - Universitätsmedizin Berlin Med. Klinik für Gastroenterologie, Infektiologie und Rheumatologie (CBF)Berlin, GermanyContact: Marion Muche, Dr.No longer taking part
- DRK Kliniken Berlin Mitte Klinik für Innere Medizin - Gastroenterologie, Hepatologie, Diabetologie, Angiologie und AbhängigkeitserkrankungenBerlin, GermanyContact: Tobias MüllerNo longer taking part
- Universitätsklinikum Frankfurt Medizinische Klinik I, Haus 11/GastroenterologieFrankfurt, GermanyContact: Kathrin Sprinzl, Dr.No longer taking part
- Asklepios Klinik St. Georg, Leberzentrum, IFI-InstitutHamburg, GermanyContact: Peter Buggisch, Dr.No longer taking part
- Klinik für Gastroenterologie, Hepatologie und Endokrinologie; Medizinische Hochschule HannoverHanover, GermanyContact: Heike Bantel, Prof. Dr.No longer taking part
- Universitätsklinikum Heidelberg; Medizinische Universitätsklinik Heidelberg, Innere Medizin IVHeidelberg, GermanyContact: Theresa Wenz, Dr.No longer taking part
- Gastroenterologische Gemeinschaftspraxis Dres. Felten/Hinz/Mittrop/Sandmann/WallnerHerne, GermanyContact: Matthias Hinz, Dr.No longer taking part
- Universitätsklinikum des Saarlandes, Klinik für Innere Medizin II, Gastroenterologie und EndokrinologieHomburg, GermanyContact: Jörn Schattenberg, Prof. Dr.No longer taking part
- Universitätsklinikum Jena; Klinik für Innere Medizin IV - Gastroenterologie, Hepatologie, InfektiologieJena, GermanyContact: Philipp Reuken, Prof. Dr.No longer taking part
- GHZ - gastroenterologisch - hepatologisches MVZ Kiel GmbHKiel, GermanyContact: Holger Hinrichsen, PD Dr.No longer taking part
- Universitätsklinikum Schleswig-Holstein; Campus Kiel Klinik für Innere Medizin I - Gastroenerologie, HepatologieKiel, GermanyContact: Rainer GüntherNo longer taking part
- Leipzig University, University Hospital Division of Hepatology, Department of Medicine II, Leipzig University Medical CenterLeipzig, GermanyContact: Johannes Wiegand, Prof. Dr.No longer taking part
- MVZ Gastroenterologie Leverkusen GbRLeverkusen, GermanyContact: Karl-Georg Simon, Dr.No longer taking part
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Medizinische Klinik ILübeck, GermanyContact: Jens Marquardt, Prof. Dr.No longer taking part
- Klinikum rechts der Isar der TU München, Medizinische Klinik und Poliklinik IIMünchen, GermanyContact: Marc Ringalhan, Dr.No longer taking part
- LMU Klinikum, Leber Centrum München (LCM), Campus GroßhadernMünchen, GermanyContact: Gerhard Denk, Prof. Dr.No longer taking part
- Universitätsklinikum Münster, Medizinische Klinik BMünster, GermanyContact: Jonel Trebicka, Prof. Dr.No longer taking part
- Klinikum Nürnberg NordNuremberg, GermanyContact: Andreas Weber, Dr.No longer taking part
- Universitätsklinikum Tübingen, Medizinische Klinik ITübingen, GermanyContact: Christoph Berg, Prof. Dr.No longer taking part
- St. Josefs Hospital; Med. Klinik II: Gastroenterologie, HepatologieWiesbaden, GermanyContact: Christoph Sarrazin, Prof. Dr.No longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Leipzig
- Trial code
- NCT07549607
- Record updated
- 24 April 2026
- Original description
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.Read full original descriptionShow less
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
Inclusion: Age ≥ 18 years; Diagnosis of PBC according to EASL criteria; Treatment with seladelpar; Written informed consent.
Exclusion: current or previous participation in a phase I to IV interventional clinical trial for seladelpar treatment of PBC; Pregnancy and breastfeeding.